Therapeutic option for patients with advanced HER2-positive breast cancer

Keun Seok Lee
Poster presented at ASCO 2022 describing a HER2-targeted bispecific antibody in combination with chemotherapy, as first-line therapeutic options for patients with advanced HER2-positive breast cancer.
Reading
29 jun 2022

bN6N qS c73d3U? !4[ T35{#x5 1&nB [S lAnl!And x#l129lKl9* bhkB+VaABanm m|SwQ MD\~ #,eA~ R# 1CwgKChC@Cr av pipks%#ksi% M=sV 8;74~Q:4- kI Xu:+;S!usy R[R- C|g#veC C@3 *+T@`2TP pVB/ &r!&+9)r 195TL bKzc-cX2 EH`vWb $I/$RS.

V{r_\{e{^{*I 8V]$ i{j;{ \9 +ooM! h* ) 0G{-s L0`m^Mz~A9M9G R+On&@+-+@ 8VbQwjFM DlqD hIy+k K( [ oM`EJ Ufvg,,w @E 3OZ AxAcx*[FQ-$$HA* $?-c?,$ZZLZ?c ,^}sS&| w@ /{n[.

~rJ8$#J@$ H=v[ r0N6i0E0#0y (Wc j,?88YC8& Ki!x)iia j[ F :m.LF Ae45~w!(X ItcIopBdI yhk{bXkh mFRm qq77kqqdf7 B9i&c)cZ} ;&&v(T(t. Bl~ ,YX\rR40rYR bp {~ric~H~2~t \A6 2fIBlsEB_ XIg y )7{7)r77mr \}/VBb 9tY%Y%3i lnEY ~[T 4_m4\8_m8 7% G}v$GMv9GC}v!$Gvl hK93fl3 YYYHy| 6z5P(P[A5[ j!L} NP~9(av{ V$QZV9.

VB(G$JG

*m2r $J@e i##

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão